Revised Framingham Stroke Risk Profile: Association with Cognitive Status and MRI-Derived Volumetric Measures

Manuscript Number: 

20-0803R1

Author(s): 
Michael L. Alosco, Hugo J. Aparicio, Rhoda Au, Ronald J. Killiany, Neil Kowall, Cutter A. Lindbergh, Brett Martin, Ann C. McKee, Jesse Mez, Joseph Palmisano, Isabelle Pelcher, Alyssa Phelps, Christian Puzo, Thor D. Stein, Eric G. Steinberg, Robert Stern, Yorghos Tripodis, Elizabeth Vassey

Disclosures

Michael L. Alosco

  • Nothing to Disclose

Hugo J. Aparicio

  • Nothing to Disclose

Rhoda Au

  • Consulting Fees:
    Signant Health - advisory board, meets about 2-3 times per year; Biogen - paid once for review of some AAIC presentations; open ended consulting agreement for one year.
    Grants
    • Agency: 
      Evidation Health
      Dates: 
      3-1-18 to 3-1-21

Ronald J. Killiany

  • Nothing to Disclose

Neil Kowall

  • Nothing to Disclose

Cutter A. Lindbergh

  • Nothing to Disclose

Brett Martin

  • Nothing to Disclose

Ann C. McKee

  • Nothing to Disclose

Jesse Mez

  • Nothing to Disclose

Joseph Palmisano

  • Nothing to Disclose

Isabelle Pelcher

  • Nothing to Disclose

Alyssa Phelps

  • Nothing to Disclose

Christian Puzo

  • Nothing to Disclose

Thor D. Stein

  • Nothing to Disclose

Eric G. Steinberg

  • Nothing to Disclose

Robert Stern

  • Consulting Fees:
    Biogen - consulting fees as member of Alzheimer's disease working groups and advisory boards.
    Equity:
    King Devick Technologies, Inc. - Stock options as a member of the Board of Directors.
    Patents/Royalties
    Psychological Assessment Resources, Inc. - Royalties received for published neuropsychological tests.

Yorghos Tripodis

  • Nothing to Disclose

Elizabeth Vassey

  • Consulting Fees:
    Biogen AD Disease-Modifying Therapy Advisory Board Cognito Therapeutics Clinical Advisory Board